Gail V W Johnson

List of Publications by Year
in descending order

222 papers	25,352 citations	8755 75 h-index	7160 153 g-index
227 all docs	227 docs citations	227 times ranked	33859 citing authors

#	Article	IF	Citations
1	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701
2	Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy, 2012, 8, 445-544.	9.1	3,122
3	The glamour and gloom of glycogen synthase kinase-3. Trends in Biochemical Sciences, 2004, 29, 95-102.	7.5	1,400
4	Tau phosphorylation in neuronal cell function and dysfunction. Journal of Cell Science, 2004, 117, 5721-5729.	2.0	506
5	Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release. Human Molecular Genetics, 2004, 13, 1407-1420.	2.9	438
6	Tau phosphorylation: physiological and pathological consequences. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2005, 1739, 280-297.	3.8	379
7	Transglutaminase Regulation of Cell Function. Physiological Reviews, 2014, 94, 383-417.	28.8	353
8	p38 Kinase Is Activated in the Alzheimer's Disease Brain. Journal of Neurochemistry, 2008, 72, 2053-2058.	3.9	341
9	Detection of Phosphorylated Ser262 in Fetal Tau, Adult Tau, and Paired Helical Filament Tau. Journal of Biological Chemistry, 1995, 270, 18917-18922.	3.4	319
10	Histone deacetylase 6 interacts with the microtubuleâ€associated protein tau. Journal of Neurochemistry, 2008, 106, 2119-2130.	3.9	312
11	The role of microtubule-associated protein 2 (MAP-2) in neuronal growth, plasticity, and degeneration. Journal of Neuroscience Research, 1992, 33, 505-512.	2.9	304
12	The Microtubule-associated Protein Tau Is Extensively Modified with O-linked N-acetylglucosamine. Journal of Biological Chemistry, 1996, 271, 28741-28744.	3.4	296
13	Nrf2 reduces levels of phosphorylated tau protein by inducing autophagy adaptor protein NDP52. Nature Communications, 2014, 5, 3496.	12.8	265
14	Direct, activating interaction between glycogen synthase kinase-3Â and p53 after DNA damage. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 7951-7955.	7.1	247
15	Insulin Transiently Increases Tau Phosphorylation. Journal of Neurochemistry, 1999, 72, 576-584.	3.9	222
16	Mitochondrial Respiration and ATP Production Are Significantly Impaired in Striatal Cells Expressing Mutant Huntingtin. Journal of Biological Chemistry, 2005, 280, 30773-30782.	3.4	221
17	Glycogen Synthase Kinase 3Î² Phosphorylates Tau at Both Primed and Unprimed Sites. Journal of Biological Chemistry, 2003, 278, 187-193.	3.4	220
18	Primed phosphorylation of tau at Thr231 by glycogen synthase kinase 3Î² (GSK3Î²) plays a critical role in regulating tau's ability to bind and stabilize microtubules. Journal of Neurochemistry, 2004, 88, 349-358.	3.9	215

#	Article	IF	Citations
19	Transglutaminase 2: A molecular Swiss army knife. Biochimica Et Biophysica Acta - Molecular Cell Research, 2012, 1823, 406-419.	4.1	202
20	Modulation of the in Situ Activity of Tissue Transglutaminase by Calcium and GTP. Journal of Biological Chemistry, 1998, 273, 2288-2295.	3.4	186
21	Degradation of Microtubule-Associated Protein 2 and Brain Spectrin by Calpain: A Comparative Study. Journal of Neurochemistry, 1991, 56, 1630-1638.	3.9	180
22	Transglutaminase activity is increased in Alzheimer's disease brain. Brain Research, 1997, 751, 323-329.	2.2	179
23	Proteolysis of tau by calpain. Biochemical and Biophysical Research Communications, 1989, 163, 1505-1511.	2.1	174
24	Tau Clearance Mechanisms and Their Possible Role in the Pathogenesis of Alzheimer Disease. Frontiers in Neurology, 2013, 4, 122.	2.4	174
25	Tau Is Hyperphosphorylated at Multiple Sites in Mouse Brain In Vivo After Streptozotocin-Induced Insulin Deficiency. Diabetes, 2006, 55, 3320-3325.	0.6	169
26	Transglutaminase and Polyamination of Tubulin: Posttranslational Modification for Stabilizing Axonal Microtubules. Neuron, 2013, 78, 109-123.	8.1	167
27	Autophagy in Alzheimerâ€™s disease. Reviews in the Neurosciences, 2015, 26, 385-95.	2.9	167
28	Tissue transglutaminase: a possible role in neurodegenerative diseases. Progress in Neurobiology, 2000, 61, 439-463.	5.7	159
29	Cystamine Inhibits Caspase Activity. Journal of Biological Chemistry, 2003, 278, 3825-3830.	3.4	155
30	The Ï„ Protein in Human Cerebrospinal Fluid in Alzheimer's Disease Consists of Proteolytically Derived Fragments. Journal of Neurochemistry, 1997, 68, 430-433.	3.9	154
31	A tau homeostasis signature is linked with the cellular and regional vulnerability of excitatory neurons to tau pathology. Nature Neuroscience, 2019, 22, 47-56.	14.8	154
32	Complement activation by neurofibrillary tangles in Alzheimer's disease. Neuroscience Letters, 2001, 305, 165-168.	2.1	153
33	Transglutaminase 2 and Its Role in Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 699-707.	5.6	151
34	Distinct Nuclear Localization and Activity of Tissue Transglutaminase. Journal of Biological Chemistry, 1998, 273, 11991-11994.	3.4	149
35	Caspase-cleaved Tau Expression Induces Mitochondrial Dysfunction in Immortalized Cortical Neurons. Journal of Biological Chemistry, 2009, 284, 18754-18766.	3.4	146
36	Tau protein is phosphorylated by cyclic AMP-dependent protein kinase and calcium/calmodulin-dependent protein kinase II within its microtubule-binding domains at Ser-262 and Ser-356. Biochemical Journal, 1996, 316, 655-660.	3.7	136

#	Article	IF	Citations
37	Role of mitochondrial dysfunction in the pathogenesis of Huntington's disease. Brain Research Bulletin, 2009, 80, 242-247.	3.0	135
38	Itâ€™s all about tau. Progress in Neurobiology, 2019, 175, 54-76.	5.7	134
39	Cyclinâ€dependent kinaseâ€5 in neurodegeneration. Journal of Neurochemistry, 2004, 88, 1313-1326.	3.9	132
40	Tissue Transglutaminase Does Not Contribute to the Formation of Mutant Huntingtin Aggregates. Journal of Cell Biology, 2001, 153, 25-34.	5.2	128
41	A Caspase Cleaved Form of Tau Is Preferentially Degraded through the Autophagy Pathway. Journal of Biological Chemistry, 2010, 285, 21978-21987.	3.4	126
42	Transient Increases in Intracellular Calcium Result in Prolonged Site-selective Increases in Tau Phosphorylation through a Glycogen Synthase Kinase 3Î²-dependent Pathway. Journal of Biological Chemistry, 1999, 274, 21395-21401.	3.4	124
43	The Role of Tau Phosphorylation in the Pathogenesis of Alzheimers Disease. Current Alzheimer Research, 2006, 3, 449-463.	1.4	124
44	Insulin-like growth factor-1 and insulin mediate transient site-selective increases in tau phosphorylation in primary cortical neurons. Neuroscience, 2000, 99, 305-316.	2.3	119
45	Rosiglitazone Treatment Prevents Mitochondrial Dysfunction in Mutant Huntingtin-expressing Cells. Journal of Biological Chemistry, 2008, 283, 25628-25637.	3.4	117
46	Mutant Huntingtin Expression Induces Mitochondrial Calcium Handling Defects in Clonal Striatal Cells. Journal of Biological Chemistry, 2006, 281, 34785-34795.	3.4	116
47	The role of tau phosphorylation and cleavage in neuronal cell death. Frontiers in Bioscience - Landmark, 2007, 12, 733.	3.0	113
48	Tissue transglutaminase is essential for neurite outgrowth in human neuroblastoma SH-SY5Y cells. Neuroscience, 2001, 102, 481-491.	2.3	112
49	Transglutaminase facilitates the formation of polymers of the Î²-amyloid peptide. Brain Research, 1994, 651, 129-133.	2.2	109
50	Transglutaminase Catalyzes the Formation of Sodium Dodecyl Sulfate-Insoluble, Alz-50-Reactive Polymers of ?. Journal of Neurochemistry, 1993, 61, 1159-1162.	3.9	107
51	Glycogen Synthase Kinase 3Î² Is Tyrosine Phosphorylated by PYK2. Biochemical and Biophysical Research Communications, 2001, 284, 485-489.	2.1	106
52	'Oxidation Inhibits Substrate Proteolysis by Calpain I but Not Autolysis. Journal of Biological Chemistry, 1997, 272, 2005-2012.	3.4	104
53	Glycogen Synthase Kinase 3Î² Induces Caspase-cleaved Tau Aggregation in Situ. Journal of Biological Chemistry, 2004, 279, 54716-54723.	3.4	104
54	Tau Protein in Normal and Alzheimer's Disease Brain: An Update*. Journal of Alzheimer's Disease, 1999, 1, 329-351.	2.6	103

#	Article	IF	Citations
55	Intracellular Localization and Activity State of Tissue Transglutaminase Differentially Impacts Cell Death. Journal of Biological Chemistry, 2004, 279, 8715-8722.	3.4	103
56	Truncated tau and Aβ cooperatively impair mitochondria in primary neurons. Neurobiology of Aging, 2012, 33, 619.e25-619.e35.	3.1	103
57	Site-specific Phosphorylation and Caspase Cleavage Differentially Impact Tau-Microtubule Interactions and Tau Aggregation. Journal of Biological Chemistry, 2006, 281, 19107-19114.	3.4	100
58	Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease. Journal of Neurochemistry, 2005, 95, 210-220.	3.9	96
59	Calpains: Intact and active?. BioEssays, 1997, 19, 1011-1018.	2.5	95
60	Transglutaminase Crossâ€Linking of the Ï„ Protein. Journal of Neurochemistry, 1995, 65, 1760-1770.	3.9	93
61	Cdk5 phosphorylates p53 and regulates its activity. Journal of Neurochemistry, 2002, 81, 307-313.	3.9	92
62	In vitro polymerization of oxidized tau into filaments. Brain Research, 1993, 613, 313-316.	2.2	89
63	The role of tau kinases in Alzheimer's disease. Current Opinion in Drug Discovery & Development, 2010, 13, 595-603.	1.9	89
64	The p38 MAP kinase signaling pathway in Alzheimer's disease. Experimental Neurology, 2003, 183, 263-268.	4.1	88
65	Mitochondrial permeability transition pore induces mitochondria injury in Huntington disease. Molecular Neurodegeneration, 2013, 8, 45.	10.8	88
66	Localization and in Situ Phosphorylation State of Nuclear Tau. Experimental Cell Research, 1995, 220, 332-337.	2.6	87
67	Oxidative Stress Inhibits Calpain Activity in Situ. Journal of Biological Chemistry, 1998, 273, 13331-13338.	3.4	87
68	Phosphorylation Modulates Calpain-Mediated Proteolysis and Calmodulin Binding of the 200-kDa and 160-kDa Neurofilament Proteins. Journal of Neurochemistry, 1993, 61, 191-199.	3.9	86
69	Fisetin stimulates autophagic degradation of phosphorylated tau via the activation of TFEB and Nrf2 transcription factors. Scientific Reports, 2016, 6, 24933.	3.3	86
70	Tau, where are we now?. Journal of Alzheimer's Disease, 2002, 4, 375-398.	2.6	83
71	Differential Binding of Apolipoprotein E Isoforms to Tau and Other Cytoskeletal Proteins. Experimental Neurology, 1996, 138, 252-260.	4.1	80
72	The Low Density Lipoprotein Receptor-related Protein 6 Interacts with Glycogen Synthase Kinase 3 and Attenuates Activity. Journal of Biological Chemistry, 2006, 281, 4787-4794.	3.4	80

#	Article	IF	Citations
73	Impaired Mitochondrial Dynamics and Nrf2 Signaling Contribute to Compromised Responses to Oxidative Stress in Striatal Cells Expressing Full-Length Mutant Huntingtin. PLoS ONE, 2013, 8, e57932.	2.5	80
74	Tissue transglutaminase contributes to disease progression in the R6/2 Huntington's disease mouse model via aggregate-independent mechanisms. Journal of Neurochemistry, 2005, 92, 83-92.	3.9	79
75	BAG3 facilitates the clearance of endogenous tau in primary neurons. Neurobiology of Aging, 2015, 36, 241-248.	3.1	79
76	Striatal cells from mutant huntingtin knock-in mice are selectively vulnerable to mitochondrial complex II inhibitor-induced cell death through a non-apoptotic pathway. Human Molecular Genetics, 2004, 13, 669-681.	2.9	78
77	Tau complexes with phospholipase C-Î³ in situ. NeuroReport, 1998, 9, 67-71.	1.2	74
78	Tissue transglutaminase differentially modulates apoptosis in a stimuli-dependent manner. Journal of Neurochemistry, 2002, 81, 780-791.	3.9	74
79	Transglutaminase 2 protects against ischemic insult, interacts with HIF1Î², and attenuates HIF1 signaling. FASEB Journal, 2008, 22, 2662-2675.	0.5	71
80	Hippocampal microtubule-associated protein-2 alterations with contextual memory1Published on the World Wide Web on 28 January 1999.1. Brain Research, 1999, 821, 241-249.	2.2	70
81	Nerve Growth Factor Protects PC12 Cells Against Peroxynitriteâ€Induced Apoptosis via a Mechanism Dependent on Phosphatidylinositol 3â€Kinase. Journal of Neurochemistry, 1997, 69, 53-59.	3.9	70
82	The protective effects of cystamine in the R6/2 Huntington's disease mouse involve mechanisms other than the inhibition of tissue transglutaminase. Neurobiology of Aging, 2006, 27, 871-879.	3.1	70
83	Split GFP complementation assay: a novel approach to quantitatively measure aggregation of tau <i>in situ</i>: effects of GSK3Î² activation and caspase 3 cleavage. Journal of Neurochemistry, 2007, 103, 2529-2539.	3.9	69
84	Aluminum impairs glucose utilization and cholinergic activity in rat brain in vitro. Toxicology, 1986, 40, 93-102.	4.2	67
85	BAG3 and SYNPO (synaptopodin) facilitate phospho-MAPT/Tau degradation via autophagy in neuronal processes. Autophagy, 2019, 15, 1199-1213.	9.1	67
86	Identification of the N-terminal functional domains of Cdk5 by molecular truncation and computer modeling. Proteins: Structure, Function and Bioinformatics, 2002, 48, 447-453.	2.6	66
87	Intracellular Localization and Conformational State of Transglutaminase 2: Implications for Cell Death. PLoS ONE, 2009, 4, e6123.	2.5	66
88	The toxicity of tau in Alzheimer disease: turnover, targets and potential therapeutics. Journal of Cellular and Molecular Medicine, 2011, 15, 1621-1635.	3.6	65
89	Epigallocatechin-3-gallate enhances clearance of phosphorylated tau in primary neurons. Nutritional Neuroscience, 2016, 19, 21-31.	3.1	65
90	Transglutaminase 2 in neurodegenerative disorders. Frontiers in Bioscience - Landmark, 2007, 12, 891.	3.0	63

#	Article	IF	Citations
91	Glycogen synthase kinase-3Î², Î²-catenin, and tau in postmortem bipolar brain. Journal of Neural Transmission, 1999, 106, 1217-1222.	2.8	62
92	The interrelationship between mitochondrial dysfunction and transcriptional dysregulation in Huntington disease. Journal of Bioenergetics and Biomembranes, 2010, 42, 199-205.	2.3	62
93	Aluminum alters cyclic AMP and cyclic GMP levels but not presynaptic cholinergic markers in rat brain in vivo. Brain Research, 1987, 403, 1-6.	2.2	61
94	Tau phosphorylation and proteolysis: Insights and perspectives. Journal of Alzheimer's Disease, 2006, 9, 243-250.	2.6	61
95	The interrelationship between selective tau phosphorylation and microtubule association. Brain Research, 1998, 798, 173-183.	2.2	60
96	Phosphorylation of rat brain cytoskeletal proteins is increased after orally administered aluminum. Brain Research, 1988, 456, 95-103.	2.2	59
97	Phosphorylation, calpain proteolysis and tubulin binding of recombinant human tau isoforms. Brain Research, 1993, 604, 32-40.	2.2	58
98	Role of the intracellular domains of LRP5 and LRP6 in activating the Wnt canonical pathway. Journal of Cellular Biochemistry, 2005, 95, 328-338.	2.6	57
99	Calpain-mediated proteolysis of microtubule-associated protein 2 (MAP-2) is inhibited by phosphorylation by cAMP-dependent protein kinase, but not by Ca2+/calmodulin-dependent protein kinase II. Journal of Neuroscience Research, 1993, 34, 642-647.	2.9	56
100	The regulatory role of calmodulin in the proteolysis of individual neurofilament proteins by calpain. Neurochemical Research, 1991, 16, 869-873.	3.3	55
101	Phosphorylated tau potentiates AÎ²-induced mitochondrial damage in mature neurons. Neurobiology of Disease, 2014, 71, 260-269.	4.4	55
102	Sulforaphane induces autophagy through ERK activation in neuronal cells. FEBS Letters, 2014, 588, 3081-3088.	2.8	55
103	Phosphorylation of Ï„ In Situ: Inhibition of Calciumâ€Đependent Proteolysis. Journal of Neurochemistry, 1995, 65, 903-911.	3.9	52
104	Modulation of tau phosphorylation and intracellular localization by cellular stress. Biochemical Journal, 2000, 345, 263-270.	3.7	51
105	Tau Protein in Normal and Alzheimer's Disease Brain*. Journal of Alzheimer's Disease, 1999, 1, 307-328.	2.6	50
106	Oral aluminum alters in vitro protein phosphorylation and kinase activities in rat brain. Neurobiology of Aging, 1990, 11, 209-216.	3.1	49
107	Nrf2 mediates the expression of BAG3 and autophagy cargo adaptor proteins and tau clearance in an age-dependent manner. Neurobiology of Aging, 2018, 63, 128-139.	3.1	49
108	Differential Phosphorylation of Ï„ by Cyclic AMPâ€Đependent Protein Kinase and Ca²⁺/Calmodulinâ€Đependent Protein Kinase II: Metabolic and Functional Consequences. Journal of Neurochemistry, 1992, 59, 2056-2062.	3.9	48

#	Article	IF	Citations
109	Endostatin and transglutaminase 2 are involved inÂfibrosis of the aging kidney. Kidney International, 2016, 89, 1281-1292.	5.2	46
110	Modulation of carbachol-stimulated inositol phospholipid hydrolysis in rat cerebral cortex. Neurochemical Research, 1987, 12, 693-700.	3.3	45
111	Mutant (R406W) Human Tau Is Hyperphosphorylated and Does Not Efficiently Bind Microtubules in a Neuronal Cortical Cell Model. Journal of Biological Chemistry, 2004, 279, 7893-7900.	3.4	45
112	Tissue transglutaminase overexpression in the brain potentiates calcium-induced hippocampal damage. Journal of Neurochemistry, 2006, 97, 582-594.	3.9	45
113	Ubiquitin-proteasome system alterations in a striatal cell model of huntington's disease. Journal of Neuroscience Research, 2007, 85, 1774-1788.	2.9	43
114	Tau Protein Is Hyperphosphorylated in a Siteâ€Specific Manner in Apoptotic Neuronal PC12 Cells. Journal of Neurochemistry, 2000, 75, 2346-2357.	3.9	43
115	Calcineurin inhibition prevents calpain-mediated proteolysis of tau in differentiated PC12 cells. Journal of Neuroscience Research, 1998, 53, 153-164.	2.9	42
116	Transglutaminase 2 protects against ischemic stroke. Neurobiology of Disease, 2010, 39, 334-343.	4.4	42
117	Complete transglutaminase 2 ablation results in reduced stroke volumes and astrocytes that exhibit increased survival in response to ischemia. Neurobiology of Disease, 2012, 45, 1042-1050.	4.4	40
118	Mechanisms of tau and Aî²-induced excitotoxicity. Brain Research, 2016, 1634, 119-131.	2.2	40
119	The Microtubule Binding of Tau and High Molecular Weight Tau in Apoptotic PC12 Cells Is Impaired because of Altered Phosphorylation. Journal of Biological Chemistry, 1999, 274, 35686-35692.	3.4	39
120	Hyperosmotic stress-induced apoptosis and tau phosphorylation in human neuroblastoma cells. Journal of Neuroscience Research, 2001, 65, 573-582.	2.9	39
121	Impaired Mitochondrial Function Results in Increased Tissue Transglutaminase Activity In Situ. Journal of Neurochemistry, 2002, 75, 1951-1961.	3.9	39
122	Activation of Glycogen Synthase Kinase 3î² Promotes the Intermolecular Association of Tau. Journal of Biological Chemistry, 2007, 282, 23410-23417.	3.4	39
123	Tissue Transglutaminase Directly Regulates Adenylyl Cyclase Resulting in Enhanced cAMP-response Element-binding Protein (CREB) Activation. Journal of Biological Chemistry, 2003, 278, 26838-26843.	3.4	38
124	Mitochondrial-targeted active Akt protects SH-SY5Y neuroblastoma cells from staurosporine-induced apoptotic cell death. Journal of Cellular Biochemistry, 2007, 102, 196-210.	2.6	38
125	Three different human tau isoforms and rat neurofilament light, middle and heavy chain proteins are cellular substrates for transglutaminase. Neuroscience Letters, 2001, 298, 9-12.	2.1	37
126	Ceramide Selectively Decreases Tau Levels in Differentiated PC12 Cells Through Modulation of Calpain I. Journal of Neurochemistry, 1997, 69, 1020-1030.	3.9	37

#	Article	IF	Citations
127	Increased glutathione levels in cortical and striatal mitochondria of the R6/2 Huntington's disease mouse model. Neuroscience Letters, 2005, 386, 63-68.	2.1	37
128	Regulated proteolytic processing of LRP6 results in release of its intracellular domain. Journal of Neurochemistry, 2007, 101, 517-529.	3.9	37
129	Developmental regulation of tissue transglutaminase in the mouse forebrain. Journal of Neurochemistry, 2004, 91, 1369-1379.	3.9	36
130	Immortalized cortical neurons expressing caspase-cleaved tau are sensitized to endoplasmic reticulum stress induced cell death. Brain Research, 2008, 1234, 206-212.	2.2	36
131	Cytosolic Guanine Nucledotide Binding Deficient Form of Transglutaminase 2 (R580a) Potentiates Cell Death in Oxygen Glucose Deprivation. PLoS ONE, 2011, 6, e16665.	2.5	36
132	Select Alterations in Protein Kinases and Phosphatases During Apoptosis of Differentiated PC12 Cells. Journal of Neurochemistry, 2002, 68, 2338-2347.	3.9	35
133	Transglutaminase 2 facilitates or ameliorates HIF signaling and ischemic cell death depending on its conformation and localization. Biochimica Et Biophysica Acta - Molecular Cell Research, 2013, 1833, 1-10.	4.1	35
134	Tauopathy-associated tau modifications selectively impact neurodegeneration and mitophagy in a novel C. elegans single-copy transgenic model. Molecular Neurodegeneration, 2020, 15, 65.	10.8	35
135	Transient oxidative stress in SH-SY5Y human neuroblastoma cells results in caspase dependent and independent cell death and tau proteolysis. Journal of Neuroscience Research, 2000, 61, 515-523.	2.9	34
136	Tau phosphorylation during apoptosis of human SH-SY5Y neuroblastoma cells. Brain Research, 2001, 921, 31-43.	2.2	34
137	Tissue Transglutaminase Is an In Situ Substrate of Calpain: Regulation of Activity. Journal of Neurochemistry, 1998, 71, 240-247.	3.9	34
138	Tissue transglutaminase triggers oligomerization and activation of dual leucine zipper-bearing kinase in calphostin C-treated cells to facilitate apoptosis. Cell Death and Differentiation, 2004, 11, 542-549.	11.2	34
139	Metabolic State Determines Sensitivity to Cellular Stress in Huntington Disease: Normalization by Activation of PPARÎ³. PLoS ONE, 2012, 7, e30406.	2.5	34
140	NDP52 associates with phosphorylated tau in brains of an Alzheimer disease mouse model. Biochemical and Biophysical Research Communications, 2014, 454, 196-201.	2.1	34
141	Metal-catalyzed oxidation of bovine neurofilaments in vitro. Free Radical Biology and Medicine, 1995, 18, 891-899.	2.9	33
142	Enhancement of Peroxynitrite-Induced Apoptosis in PC12 Cells by Fibroblast Growth Factor-1 and Nerve Growth Factor Requires p21Ras Activation and Is Suppressed by Bcl-2. Archives of Biochemistry and Biophysics, 1998, 356, 41-45.	3.0	33
143	Ï„ Selfâ€Association: Stabilization with a Chemical Crossâ€Linker and Modulation by Phosphorylation and Oxidation State. Journal of Neurochemistry, 1995, 64, 1209-1215.	3.9	33
144	AES/GRG5: More than just a dominantâ€negative TLE/GRG family member. Developmental Dynamics, 2010, 239, 2795-2805.	1.8	33

#	Article	IF	Citations
145	Proteolysis of Microtubule-Associated Protein 2 and Tubulin by Cathepsin D. Journal of Neurochemistry, 1991, 57, 1577-1583.	3.9	32
146	Pavlovian conditioning alters cortical microtubule-associated protein-2. NeuroReport, 1994, 5, 1045-1048.	1.2	32
147	Does tissue transglutaminase play a role in Huntington's disease?. Neurochemistry International, 2002, 40, 37-52.	3.8	32
148	Understanding the hyperphosphorylation of tau in Alzheimer's disease: Importance of examining site-specific phosphorylation in non-disease systems. Neurobiology of Aging, 1995, 16, 371-374.	3.1	31
149	Tissue Transglutaminase Selectively Modifies Proteins Associated with Truncated Mutant Huntingtin in Intact Cells. Neurobiology of Disease, 2001, 8, 391-404.	4.4	31
150	Tau and HMW tau phosphorylation and compartmentalization in apoptotic neuronal PC12 cells. Journal of Neuroscience Research, 2001, 66, 203-213.	2.9	28
151	Validity of mouse models for the study of tissue transglutaminase in neurodegenerative diseases. Molecular and Cellular Neurosciences, 2004, 25, 493-503.	2.2	28
152	Effects of cyclin-dependent kinase-5 activity on apoptosis and tau phosphorylation in immortalized mouse brain cortical cells. Journal of Neuroscience Research, 2004, 76, 110-120.	2.9	27
153	Immunoblot analysis reveals that isopeptide antibodies do not specifically recognize the Îµ-(Î³-glutamyl)lysine bonds formed by transglutaminase activity. Journal of Neuroscience Methods, 2004, 134, 151-158.	2.5	26
154	Vena cava and aortic smooth muscle cells express transglutaminases 1 and 4 in addition to transglutaminase 2. American Journal of Physiology - Heart and Circulatory Physiology, 2012, 302, H1355-H1366.	3.2	26
155	The Crosstalk Between Pathological Tau Phosphorylation and Mitochondrial Dysfunction as a Key to Understanding and Treating Alzheimerâ€™s Disease. Molecular Neurobiology, 2020, 57, 5103-5120.	4.0	26
156	Dose- and time-dependent hippocampal cholinergic lesions induced by ethylcholine mustard aziridinium ion: Effects of nerve growth factor, GM1 ganglioside, and vitamin E. Neurochemical Research, 1988, 13, 685-692.	3.3	25
157	Energy metabolism and protein phosphorylation during apoptosis: a phosphorylation study of tau and high-molecular-weight tau in differentiated PC12 cells*. Biochemical Journal, 1999, 340, 51-58.	3.7	25
158	The Last Tangle of Tau. Journal of Alzheimer's Disease, 2008, 14, 441-447.	2.6	25
159	Compromised mitochondrial function results in dephosphorylation of tau through a calcium-dependent process in rat brain cerebral cortical slices. Neurochemical Research, 1994, 19, 1151-1158.	3.3	24
160	Microtubule/MAPâ€Affinity Regulating Kinase (MARK) Is Activated by Phenylarsine Oxide In Situ and Phosphorylates Tau Within Its Microtubuleâ€Binding Domain. Journal of Neurochemistry, 2000, 74, 1463-1468.	3.9	23
161	Tau facilitates AÎ²-induced loss of mitochondrial membrane potential independent of cytosolic calcium fluxes in mouse cortical neurons. Neuroscience Letters, 2015, 597, 32-37.	2.1	23
162	Axin negatively affects tau phosphorylation by glycogen synthase kinase 3Î². Journal of Neurochemistry, 2002, 83, 904-913.	3.9	22

#	Article	IF	Citations
163	Type 2 transglutaminase differentially modulates striatal cell death in the presence of wild type or mutant huntingtin. Journal of Neurochemistry, 2007, 102, 25-36.	3.9	22
164	Split GFP Complementation Assay for Quantitative Measurement of Tau Aggregation In Situ. Methods in Molecular Biology, 2010, 670, 109-123.	0.9	22
165	Transglutaminase 2: Friend or foe? The discordant role in neurons and astrocytes. Journal of Neuroscience Research, 2018, 96, 1150-1158.	2.9	22
166	Postnatal changes in serine/threonine protein phosphatases and their association with the microtubules. Developmental Brain Research, 1995, 90, 54-61.	1.7	21
167	Novel bimodal effects of the G-protein tissue transglutaminase on adrenoreceptor signalling. Biochemical Journal, 1999, 343, 541-549.	3.7	20
168	Increased expression of Bim contributes to the potentiation of serum deprivation-induced apoptotic cell death in Huntington's disease knock-in striatal cell line. Neurological Research, 2009, 31, 77-83.	1.3	20
169	Transglutaminase 2 modulation of NF-Î°B signaling in astrocytes is independent of its ability to mediate astrocytic viability in ischemic injury. Brain Research, 2017, 1668, 1-11.	2.2	20
170	Seizureâ€Induced Protein Tyrosine Phosphorylation in Rat Brain Regions. Epilepsia, 1991, 32, 755-760.	5.1	19
171	Aluminum Increases Agonist-Stimulated Cyclic AMP Production in Rat Cerebral Cortical Slices. Journal of Neurochemistry, 1989, 53, 258-263.	3.9	18
172	Phosphorylation of microtubule-associated protein tau on Ser 262 by an embryonic 100 kDa protein kinase. Brain Research, 1997, 767, 305-313.	2.2	18
173	Transglutaminases in Neurodegenerative Disorders. , 2005, 38, 139-157.		18
174	FRAT-2 Preferentially Increases Glycogen Synthase Kinase 3Î²-mediated Phosphorylation of Primed Sites, Which Results in Enhanced Tau Phosphorylation. Journal of Biological Chemistry, 2005, 280, 270-276.	3.4	18
175	The role of BAG3 in health and disease: A â€œMagic BAG of Tricksâ€. Journal of Cellular Biochemistry, 2022, 123, 4-21.	2.6	18
176	The Application Of Permanent Middle Cerebral Artery Ligation in the Mouse. Journal of Visualized Experiments, 2011, , .	0.3	17
177	Assessing the degradation of tau in primary neurons: The role of autophagy. Methods in Cell Biology, 2017, 141, 229-244.	1.1	17
178	Tau Clearance Mechanisms. Advances in Experimental Medicine and Biology, 2019, 1184, 57-68.	1.6	17
179	Modulation of tau phosphorylation and intracellular localization by cellular stress. Biochemical Journal, 2000, 345, 263.	3.7	16
180	Presenilin 1 Regulates Membrane Homeostatic Pathways that are Dysregulated in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2020, 77, 961-977.	2.6	15

#	Article	IF	Citations
181	Differential Modulation of TCF/LEF-1 Activity by the Soluble LRP6-ICD. PLoS ONE, 2010, 5, e11821.	2.5	15
182	Rapid, single-step procedure for the identification of transglutaminase-mediated isopeptide crosslinks in amino acid digests. Biomedical Applications, 1999, 732, 65-72.	1.7	14
183	14-3-3Î¶ does not increase GSK3Î²-mediated tau phosphorylation in cell culture models. Neuroscience Letters, 2005, 384, 211-216.	2.1	14
184	Tissue Transglutaminase-Mediated AT1 Receptor Sensitization Underlies Pro-inflammatory Cytokine LIGHT-Induced Hypertension. American Journal of Hypertension, 2019, 32, 476-485.	2.0	14
185	Tau Post-Translational Modifications: Potentiators of Selective Vulnerability in Sporadic Alzheimerâ€™s Disease. Biology, 2021, 10, 1047.	2.8	14
186	Choline Uptake, Acetylcholine Synthesis and Release, and Halothane Effects in Synaptosomes. Anesthesia and Analgesia, 1985, 64, 395???399.	2.2	13
187	The complex role of transglutaminase 2 in glioblastoma proliferation. Neuro-Oncology, 2016, 19, now157.	1.2	13
188	Depletion of transglutaminase 2 in neurons alters expression of extracellular matrix and signal transduction genes and compromises cell viability. Molecular and Cellular Neurosciences, 2018, 86, 72-80.	2.2	13
189	Depletion of astrocytic transglutaminase 2 improves injury outcomes. Molecular and Cellular Neurosciences, 2018, 92, 128-136.	2.2	13
190	Inhibition or ablation of transglutaminase 2 impairs astrocyte migration. Biochemical and Biophysical Research Communications, 2017, 482, 942-947.	2.1	12
191	The role of transglutaminase 2 in mediating glial cell function and pathophysiology in the central nervous system. Analytical Biochemistry, 2020, 591, 113556.	2.4	12
192	Cholinergic- and stress-induced signaling activities in cells overexpressing wild-type and mutant presenilin-1. Brain Research, 2001, 903, 226-230.	2.2	11
193	Verification of somatic CAG repeat expansion by pre-PCR fractionation. Journal of Neuroscience Methods, 2005, 144, 11-17.	2.5	11
194	Subcellular localization patterns of transglutaminase 2 in astrocytes and neurons are differentially altered by hypoxia. NeuroReport, 2017, 28, 1208-1214.	1.2	11
195	Aluminum increases cyclic AMP in rat cerebral cortex. Life Sciences, 1986, 39, 1301-1305.	4.3	10
196	Phosphorylation of PPP(S/T)P motif of the free LRP6 intracellular domain is not required to activate the Wnt/Î²â€catenin pathway and attenuate GSK3Î² activity. Journal of Cellular Biochemistry, 2009, 108, 886-895.	2.6	10
197	Transglutaminase 2 as a therapeutic target for neurological conditions. Expert Opinion on Therapeutic Targets, 2021, 25, 721-731.	3.4	10
198	BAG3 Regulation of RAB35 Mediates the Endosomal Sorting Complexes Required for Transport/Endolysosome Pathway and Tau Clearance. Biological Psychiatry, 2022, 92, 10-24.	1.3	10

#	Article	IF	Citations
199	The effects of aluminum on agonist-induced alterations in cyclic AMP and cyclic GMP concentrations in rat brain regions in vivo. Toxicology, 1988, 51, 299-308.	4.2	9
200	Energy metabolism and protein phosphorylation during apoptosis: a phosphorylation study of tau and high-molecular-weight tau in differentiated PC12 cells*. Biochemical Journal, 1999, 340, 51.	3.7	9
201	Measurement of Calpain Activity In Vitro and In Situ Using a Fluorescent Compound and Tau as Substrates. , 2000, 144, 143-150.		9
202	Mutant huntingtin aggregates do not sensitize cells to apoptotic stressors. FEBS Letters, 2002, 515, 61-65.	2.8	8
203	Decreases in valosin-containing protein result in increased levels of tau phosphorylated at Ser262/356. FEBS Letters, 2011, 585, 3424-3429.	2.8	8
204	Transient osmotic stress facilitates mutant huntingtin aggregation. NeuroReport, 2002, 13, 2543-2546.	1.2	7
205	New application of Î²â€galactosidase complementation to monitor tau selfâ€association. Journal of Neurochemistry, 2008, 106, 1545-1551.	3.9	7
206	Nuclear transglutaminase 2 directly regulates expression of cathepsin S in rat cortical neurons. European Journal of Neuroscience, 2018, 48, 3043-3051.	2.6	7
207	Neurotoxic Effects of Dietary Aluminium. Novartis Foundation Symposium, 1992, 169, 254-267.	1.1	7
208	Deletion or Inhibition of Astrocytic Transglutaminase 2 Promotes Functional Recovery after Spinal Cord Injury. Cells, 2021, 10, 2942.	4.1	7
209	In vitro measurements of cholinergic activity in brain regions of hibernating ground squirrels. Brain Research Bulletin, 1987, 18, 663-667.	3.0	6
210	Alterations of choline acetyltransferase, phosphoinositide hydrolysis, and cytoskeletal proteins in rat brain in response to colchicine administration. Experimental Brain Research, 1992, 89, 496-500.	1.5	6
211	Novel bimodal effects of the G-protein tissue transglutaminase on adrenoreceptor signalling. Biochemical Journal, 1999, 343, 541.	3.7	5
212	Tissue transglutaminase is not involved in the aggregate formation of stably expressed Î±-synuclein in sh-sy5y human neuroblastoma cells. Archives of Pharmacal Research, 2004, 27, 850-856.	6.3	5
213	Commentary: BAG3 as a Mediator of Endosome Function and Tau Clearance. Neuroscience, 2023, 518, 4-9.	2.3	4
214	Halothane-Induced Alterations of Glucose and Pyruvate Metabolism in Rat Cerebra Synaptosomes. Journal of Neurochemistry, 1985, 44, 1838-1844.	3.9	2
215	Metal (Fe3+) affinity chromatography: differential adsorption of tau phosphoproteins. Journal of Neuroscience Methods, 1993, 46, 245-249.	2.5	2
216	Monoclonal antibody Alz-50 reacts with bovine and human serum albumin. Journal of Neuroscience Research, 1994, 39, 589-594.	2.9	2

#	Article	IF	Citations
217	Brain casein kinase 2: Affinity purification procedure using immobilized polyethylenimine. Protein Expression and Purification, 1992, 3, 355-361.	1.3	1
218	Involvement of the low-affinity neurotrophin receptor (p75NTR) in apoptosis of differentiated PC12 cells. Neuroscience Research Communications, 1997, 20, 137-146.	0.2	1
219	Cyclin-dependent kinase-5 in neurodegeneration. Journal of Neurochemistry, 2004, 89, 528-528.	3.9	1
220	A T231E Mutant that Mimics Pathologic Phosphorylation of Tau in Alzheimer's disease Causes Activation of the Mitochondrial Unfolded Protein Response in touch neurons. MicroPublication Biology, 2020, 2020, .	0.1	1
221	P1-005: SELECTIVELY ENHANCING PATHOLOGICAL FORMS OF TAU VIA THE AUTOPHAGY PATHWAY. , 2014, 10, P306-P306.		0
222	Transglutaminases and Neurological Diseases. , 2015, , 283-314.		0